Study Provides Insight on Medtronic, Inc. CoreValve(R) System Implants Through Subclavian Approach

PARIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today issued a statement on results of clinical data presented at EuroPCR 2011 that show the Medtronic CoreValve® System, delivered through a new approach beneath the collarbone, achieved excellent procedural success rates and low in-hospital complication rates. The new approach, via subclavian access, received CE (Conformité Européenne) Mark in December and has been used primarily for people whose femoral arteries are too narrow or are compromised due to disease.